Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure†

Erland Erdmann(University of Cologne), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Markku S. Nieminen(Cornell University), Veselin Mitrović, Mihai Gheorghiade(Northwestern University), Marc J. Semigran(Healthwise), Rahul Agrawal(University of Utah)
European Heart Journal
July 9, 2012
10.1093/eurheartj/ehs196
Cited by 155

Related Papers

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
|The Lancet|2002|5.4k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
|The Lancet|2005|2.9k